Filed by Castlight Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Jiff, Inc. Registration Statement No: 333-215861

The following is an investor presentation given by Castlight Health, Inc. on March 7, 2017:

Investor Overview

March 7, 2017



Safe Harbor Statement

castlight

This presentation contains forward-looking statements regarding our trends, our strategies and the anticipated performance of our business, including our guidance for the full year of 2017. These statements are made as of today, and reflect management's current views and expectations, and are subject to various risks, uncertainties and assumptions. If this presentation is viewed after today, the information in the presentation may no longer be current or accurate. We disclaim any obligation to update or revise any forward-looking statements.

Please refer to the Company's fourth quarter and full year 2017 financial results press release dated February 15, 2017, and the risk factors included in the company's filings with the Securities and Exchange Commission for discussion of important factors that may cause actual events or results to differ materially from those contained in our forward-looking statements.

The guidance provided in this presentation was made on February 15, 2017. The Company does not update its guidance intra-quarter through investor presentations such as this.

This presentation also includes certain non-GAAP metrics, such as non-GAAP gross margin, operating expenses, and operating loss, that we believe aid in the understanding of our financial results. A reconciliation to comparable GAAP metrics, on a historical basis, can be found in the appendix section of this presentation.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

In connection with the proposed transaction between Castlight and Jiff, Castlight has filed a registration statement on Form S-4 with the SEC (Registration Statement No. 333-215861), and this registration statement, as amended, was declared effective by the SEC on February 14, 2017. This registration statement contains a joint proxy statement/prospectus/information statement and relevant materials concerning the proposed transaction. Castlight and Jiff mailed the definitive joint proxy statement/prospectus/information statement to their respective stockholders on February 24, 2017. Additionally, Castlight intends to file with the SEC other relevant materials in connection with the proposed transaction. STOCKHOLDERS OF CASTLIGHT AND JIFF ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS/INFORMATION STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents free of charge at the SEC's web site,

http://www.sec.gov. Documents will also be available for free from Castlight at www.castlighthealth.com.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed transaction shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Castlight and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Castlight's stockholders with respect of the matters relating to the proposed transaction. Jiff and its officers and directors may also be deemed a participant in such solicitation. Information regarding any interest that Castlight, Jiff or any of the executive officers or directors of Castlight or Jiff may have in the proposed transaction with Jiff is included in the joint proxy statement/prospectus/information statement that Castlight has filed with the SEC in connection with its stockholder vote on matters relating to the proposed transaction. Information about the directors and executive officers of Castlight, including their respective interest in security holding of Castlight, is set forth in the proxy statement for Castlight's 2016 Annual Meeting of Stockholders, which was filed with the SEC on April 29, 2016. Stockholders may obtain additional information regarding the interest of such participants by reading the definitive joint proxy statement/prospectus/information statement regarding the proposed transaction when it becomes available. These documents can be obtained free of charge from the sources indicated above.

Legend



Castlight is a health benefits platform that engages employees to make better health decisions and enables benefit leaders to communicate and measure their programs

| 4

Health Benefits Today: low engagement & poor health decisions

castlight

73% of employees don't fully understand their health benefits

Program utilization is typically lower than 10%

Employees pay up to 10X more for the same service

Up to 20% of surgeries are unnecessary

5-6% increase in health spending each year for employers

Why aren't employees engaged?



Explosion of vendors



Soaring consumer expectations

+

Convoluted healthcare system

6



The Castlight Health Benefits Platform

One end-to-end platform



Integrate

Simple, integrated way to

help UNDERSTAND &

ACCESS benefits



Engage

Targeted, timely communications to **GUIDE** employees to better decisions



Evaluate

Real-time **INSIGHT** into engagement with benefits and programs

8



Engage

Personalized employee experience based on their health journey







Jiff The Jiff Wellbeing Platform

Central hub for wellbeing that drives employee engagement

App store approach integrates with over 50+ solutions that sync seamlessly

Mobile-first technology with a worldclass user experience

Model: PEPM-based subscription and service fees, contract terms typically three-years paid monthly, quarterly or annually

Jiff's Motivating User Experience



Personalized incentives

Rewards tied to specific micro-behaviors that meet users where they are.

Game mechanics

Principles from online games and behavior science that make products stickier.

Everyday engagement

Engage the user every day with opportunities to stay healthy or improve health.

Mobile-first design

A consumer grade product that is always in your pocket, and easy to use.

Jiff's Ecosystem & Deep Partner Integrations



Joint Value Proposition

Simplify navigation for all benefit resources, globally



The Power of the Castlight-Jiff Combination

JIff + castlight

Most Comprehensive Health Benefits Platform

- Addresses total employee population spanning wellbeing (Jiff) and decision support (CSLT)
- Strong differentiation across product breadth, data, personalization, and ecosystem partnerships
- Complementary strengths
 in channel partnerships

castlight

Accelerated Growth Profile

- Expected 2017 pro forma non-GAAP revenue:
 - \$138-\$142 million for the combined business
 - Combined business growth of 27%-30% (vs. 21% for CSLT standalone)

Increased Scale

- Combined business creates a clear path to larger scale, faster growth
- Cost efficiencies driven by highly complementary business models

Financial Update



Executed on key priorities in 2016

2016 execution provides a strong start to 2017



Set foundation for long-term growth



Ramped adoption of our platform offering



Drove the business towards cash flow breakeven



Strong Balance Sheet

On a stand-alone basis, Castlight expects to reach cash flow breakeven by mid-2017



Guidance

Castlight plans to provide GAAP revenue guidance for the combined company when it announces financial results for the first quarter of 2017

castlight + JIff castlight **Combined Pro Forma** Standalone Pro Forma · Standalone revenue of \$123M at the high-end 2017 non-GAAP rev. range: \$138M to \$142M* · Assumptions at the high-end of the range: Non-GAAP operating loss of approximately Castlight at \$123M \$9M to \$11M Jiff at \$19M Non-GAAP net loss per share of \$0.08 to \$0.10 · 27%-30% year-over-year growth based on approximately 107M to 108M shares · Expect to reach cash flow breakeven by the end of 2018 with a cash balance of \$60M or greater * Assumes a full year of revenue contribution from Jiff and no impact from purchase accounting adjustments associated with purchase accounting for GAAP purposes.

castlight

21

2017 Key Priorities: Focus on Growth



Investor Overview

March 2017



Appendix

March 2017



Castlight's Business Model & Go-To-Market

castlight

Business Model

- Platform sold on a price per employee per month (PEPM) basis
- Typically three-year contracts
- Long-term gross margin target range of 70%-75%

Target Customers

- · Targets US self-insured employers
- Platform purchased by health benefits manager/HR
- 211 customers, including 60+ Fortune 500

Go-To-Market

- Direct sales team/channel partner approach
- Strategic relationships with Anthem and SAP
- Expanding relationships with health benefits consultants

Jiff Transaction Terms

castlight

Consideration

Castlight to issue approximately 27M shares and options

Earnout

- Issuance of up to 4M shares issuable upon achievement of specific growth objectives for the Jiff business in FY 2017
- 3M additional shares upon Jiff achieving \$25M in net new bookings
- 1M additional shares upon Jiff achieving \$25M in GAAP revenue

Pro Forma Ownership

Castlight shareholders to own ~80% of Company and Jiff shareholders to own ~20% of the combined company on a fully-diluted basis

Pro Forma Ownership

- · John Doyle to become CEO of combined company
- · Derek Newell to become President of combined company
- · Giovanni Colella will continue in role of executive chairman
- · Two members of current Jiff board will be appointed to Castlight board

Closing Conditions

- Subject to satisfaction of customary closing conditions, including approval from Castlight's stockholders with respect to the issuance of Castlight shares in the transaction
- · Expected to close at the end of 1Q 2017

Gross Profit: Reconciliation of GAAP to Non-GAAP

	Three Months Ended									
	Dec	ember 31,	N	March 31,		June 30,	September 30, De			cember 31
		2015		2016		2016		2016		2016
Gross profit:										
GAAP gross profit subscription	\$	16,048	\$	16,901	\$	17,861	\$	19,879	\$	23,912
Stock-based compensation		87		108		120		139		139
Amortization of internal-use software		124		244		244		244		244
Reduction in workforce		-		1.50		5				(573)
Non-GAAP gross profit subscription	\$	16,259	\$	17,253	\$	18,230	\$	20,262	\$	24,295
GAAP gross margin subscription		80.5%		80.3%		81.4%		83.3%		84.9%
Non-GAAP gross margin subscription		81.6%		81.9%		83.0%		84.9%		86.3%
GAAP gross loss professional services	\$	(4,388)	\$	(3,433)	\$	(3,220)	\$	(2,344)	\$	(2,417
Stock-based compensation		653		477		535		456		493
Capitalization of internal-use software		(30)		-		2		2		
Reduction in workforce		-		17.1		99		4		670
Non-GAAP gross loss professional services	\$	(3,765)	\$	(2,956)	\$	(2,586)	\$	(1,884)	\$	(1,924
GAAP gross margin professional services		(318)%		(204)%		(198)%		(143)%		(139)%
Non-GAAP gross margin professional services	,	(272)%		(176)%	•	(159)%	•	(115)%		(111)%
SAAP gross profit	\$	11,660	\$	13,468	\$	14,641	\$	17,535	\$	21,495
mpact of non-GAAP adjustments		834		829		1,003		843		876
Non-GAAP gross profit	\$	12,494	\$	14,297	\$	15,644	\$	18,378	\$	22,371
GAAP gross margin		54.7%		59.3%		62.1%		68.8%		71.9%
Non-GAAP gross margin		58.6%		62.9%		66.3%		72.1%		74.8%

castlight

| 27

Operating Expense: Reconciliation of GAAP to Non-GAAP

	Three Months Ended								
	Dec	ember 31,	M	larch 31,	J		Sep	tember 30, Dec	
Operating expense:	23	2015		2016		2016		2016	2016
GAAP sales and marketing	Ś	16,579	Ś	16,282	Ś	15,452	¢	13,143 Ś	13,923
Stock-based compensation	Ŷ	(1,822)	4	(2,235)	Ŷ	(2,219)		(2,190)	(2,199
Reduction in workforce		(1,022)		(2,200)		(374)		(48)	(2,200
Non-GAAP sales and marketing	\$	14,757	\$	14,047	\$	12,859		10,905 \$	11,724
GAAP research and development	\$	8,224	\$	10,085	\$	9,961	\$	10,573 \$	9,841
Stock-based compensation		(1,154)		(1,405)		(1,264)		(1,631)	(1,659
Capitalization of internal-use software		620		-		-		-	-
Reduction in workforce				12		(118)		(18)	220
Non-GAAP research and development	\$	7,690	\$	8,680	\$	8,579	\$	8,924 \$	8,18
GAAP general and administrative	\$	5,983	\$	8,545	\$	6,019	\$	5,338 \$	6,95
Stock-based compensation		(1,069)		(1,269)		(971)		(1,236)	(1,26
Litigation settlement		-		(2,735)		(141)		-	-
Reduction in workforce				15		(80)		(10)	-
Acquisition expenses				14		×		-	(1,73
Non-GAAP general and administrative	\$	4,914	\$	4,541	\$	4,827	\$	4,092 \$	3,95
GAAP operating expense	\$	30,786	\$	34,912	\$	31,432		29,054 \$	30,72
Impact of non-GAAP adjustments		(3,425)		(7,644)	-	(5,167)		(5,133)	(6,85
Non-GAAP operating expense	\$	27,361	\$	27,268	\$	26,265	\$	23,921 \$	23,86
Operating loss:									
GAAP operating loss	\$	(19,126)	\$	(21,444)	\$	(16,791)	\$	(11,519) \$	(9,22
Impact of non-GAAP adjustments		4,259		8,473		6,170		5,976	7,73
Non-GAAP operating loss	\$	(14,867)	\$	(12,971)	\$	(10,621)	\$	(5,543) \$	(1,49

28